Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-centre, Drug-drug Interaction Study to Assess the Effect of Voglibose (0.2 mg Tid) on the Pharmacokinetics, Safety and Tolerability of Single Oral Administration of Dapagliflozin (10 mg) in Japanese Patients With Type 2 Diabetes

NCT01055652 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01055652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01055652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-centre, Drug-drug Interaction Study to Assess the Effect of Voglibose (0.2 mg Tid) on the Pharmacokinetics, Safety and Tolerability of Single Oral Administration of Dapagliflozin (10 mg) in Japanese Patients With Type 2 Diabetes
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2010
Completion date
April 30, 2010
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus